Since our start in October 2007 ...
... as a junior group in the Cluster of Excellence "CellNetworks" and the Dept. of Infectious Diseases at the Medical Faculty at University of Heidelberg (Germany) ...
... we work on gene therapy with AAV ...
... i.e., non-pathogenic Adeno-associated viruses, which are the most promising and most versatile viral vector for therapeutic gene transfer and which we engineer ...
... using a large portfolio of technologies ...
... such as DNA shuffling, peptide display, DNA/RNA barcoding, high-throughput in vivo screening in small or large animals, single-cell (sc)RNA sequencing ...
... and targeting a variety of diseases ...
... including infection with SARS-CoV-2 (Covid-19), human immunodeficiency virus (HIV; AIDS), hepatitis viruses (HB/D/EV), or disorders of the muscle, liver, CNS, eye ...
... at our various locations in Heidelberg ...
--- comprising our different labs over 4 floors at the BioQuant center (in the middle of the campus) and our Business Unit together with the company Sirion ...
... with a diverse and ever increasing team
... currently composed of 6 postdocs, 6 PhD students, 2 MD students, 4 technicians, 1 MSc student and 1 BSc student, which we constantly aim to expand (see --> JOBS)